Press Releases

Our latest news and press releases

Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1)

Read more

Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Read more

Cellectis Provides Full Report for Second Quarter 2023 Financial Results

Read more

Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023

Read more

Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023

Read more

Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors

Read more

Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023

Read more

Cellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA) 2023

Read more

Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event

Read more

Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies

Read more